Conflicting results for lamivudine/abacavir in ART-naive patients

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1652, 2008-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Abacavir and lamivudine combination

By Somboonwit Charurut   Kurtyka Don   Paula Velez Ana  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, Iss. 12, 2009-12 ,pp. : 1599-1606

Informa Healthcare

Access to resources Recommend Favorite

Raltegravir rewards reinforced in ART-naive HIV-1 infections

By  

Inpharma, Vol. 1, Iss. 1651, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Lamivudine/abacavir [Kivexa; GlaxoSmithKline] has been launched in the UK and Germany

By  

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Long-Term Safety and Tolerability of the Lamivudine/Abacavir Combination as Components of Highly Active Antiretroviral Therapy

By Castillo Steve A.   Hernandez Jaime E.   Brothers Cindy H.  

Drug Safety, Vol. 29, Iss. 9, 2006-01 ,pp. : 811-826

Adis International

Access to resources Recommend Favorite

Dolutegravir, abacavir and lamivudine as HIV therapy

By Fernandez-Montero Jose Vicente   Barreiro Pablo   Labarga Pablo   De Mendoza Carmen   Soriano Vicente  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 1051-1057

Informa Healthcare

Access to resources Recommend Favorite